[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].

Objective: To investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer(PCa) by comparison with zoledronic acid.Methods: We assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP(n = 31) and zoledronic acid(n = 24),the former injected intravenously at the dose of 37.0 MBq/kg body weight,and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride.We performed 99mTc-MDP bone scan before and 1-2 months after the treatment.Results: The rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group(P = 0.035),and that of bone metabolism change was 64.5% in the former and 33.3% in the latter(P = 0.022).Conclusion: 153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.